Circadin is safe to use for treating insomnia

Comparing the rate of with adverse events per 100 patient weeks, the rate was higher for placebo than Circadin

Circadin has a favourable safety profile, with no obvious differences in safety parameters between the active treatment and the placebo group

---

References

1. Circadin SmPC, EPAR, Assessment Report for Circadin . Procedure No. EMEA /H/C/695. 2007. www.emea.europa.eu/humandocs/Humans/EPAR/circadin/circadin.html

2. Lemoine P, Nir T, Laudon M, Zisapel N. Pro-longed-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res 2007; 16: 372-380